Asia-Pacific Liver Cancer Therapeutics Market was worth $115.74 million in 2019 and estimated to be growing at a CAGR of 10.05%, to reach $186.83 million by 2024.
Recent advances in the treatment for primary liver cancer might deliver some stimulating pointers mainly in the Asian market where sickness and ethnic characteristics demand assessment.
In the Developing regions, such as East and South-East Asia liver cancer is the third most common tumour and the second primary cause of death. Treatment for liver cancer is reliant on numerous factors such as size, type and age of the tumour and whether the cancer has extended outside the liver.
Asia Pacific characterises as the fastest growing liver cancer treatment market owing to the rising geriatric populations. This increasing number of liver cancer cases in the Asian countries involves huge number of drugs for the treatment or prevention of liver cancer and tumours. Further, growing healthcare expenditure and increasing government initiatives are also augmenting the growth of this market. Huge capital investment is a key restraint hindering the growth of the market.
This research report segmented and sub-segmented into the following categories:
By Type: Primary, Secondary And Benign Liver Growths
By Therapeutics: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma And Targeted Therapy
By End-User: Pediatrics And Adults
By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC
Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.
China is the country in terms of revenue of the market for this region while India and Japan are projected to grow at a high rate in the forecast period.
The Top companies leading in the APAC Liver Cancer Therapeutics Market profiled in the report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.3 Benign Liver growths
5.2 By Therapeutics
5.2.1 Hepatocellular Carcinoma
5.2.2 Cholangio carcinoma
5.2.4 Targeted Therapy
5.3 By End-Users
6. Geographical Analysis
6.5 South Korea
7. Pipeline Product Analysis
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Alnylam Pharmaceuticals Inc.
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 ImClone Systems Inc.
9.3 Onyx Pharmaceuticals Inc.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Pfizer Inc.
9.6 ArQule Inc.
9.7 Jennerex Biotherapeutics Inc.
9.8 Celsion Corp.
9.9 Bayer Schering Pharma AG
9.10 4SC AG
9.11 Bristol-Myers Squibb Company
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
a) List of Tables
b) List of Figures